Calcium channel blockers

DGAP-News: Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)

Retrieved on: 
Monday, September 6, 2021

The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.

Key Points: 
  • The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.
  • Tranche 4 consists of EUR 7.5 million and will primarily be used to support the Company's development programs in diseases of the central nervous system.
  • The first three tranches of the loan totaling EUR 25 million were received by Newron in 2019 and 2020.
  • Newron is developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)

Retrieved on: 
Monday, September 6, 2021

The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.

Key Points: 
  • The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.
  • Tranche 4 consists of EUR 7.5 million and will primarily be used to support the Companys development programs in diseases of the central nervous system.
  • The first three tranches of the loan totaling EUR 25 million were received by Newron in 2019 and 2020.
  • Newron is developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

Newron Announces 2020 Financial Results and Provides Outlook For 2021

Retrieved on: 
Tuesday, March 16, 2021

Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the year ended December 31, 2020, and provided an outlook for 2021.

Key Points: 
  • Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the year ended December 31, 2020, and provided an outlook for 2021.
  • Other current financial assets) as of December 31, 2020 is EUR 31.3 million
    The onset of the COVID-19 pandemic in 2020 presented enormous challenges for societies across the world.
  • 2020 has demonstrated that Newrons business remains resilient, and we move into 2021 and beyond confident in our strategy for the future.
  • Given Newrons extensive experience in the development of Xadago/safinamide, Newron and Zambon have agreed on Newron taking responsibility for conducting the study.

DGAP-News: Newron announces 2020 financial results and provides outlook for 2021

Retrieved on: 
Tuesday, March 16, 2021

Milan, Italy, March 16, 2021 - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the year ended December 31, 2020, and provided an outlook for 2021.

Key Points: 
  • Milan, Italy, March 16, 2021 - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the year ended December 31, 2020, and provided an outlook for 2021.
  • Other current financial assets) as of December 31, 2020 is EUR 31.3 million
    "The onset of the COVID-19 pandemic in 2020 presented enormous challenges for societies across the world.
  • 2020 has demonstrated that Newron's business remains resilient, and we move into 2021 and beyond confident in our strategy for the future.
  • Given Newron's extensive experience in the development of Xadago(R)/safinamide, Newron and Zambon have agreed on Newron taking responsibility for conducting the study.

DGAP-News: Newron and Zambon sign agreement for potentially pivotal study with safinamide in Parkinson's disease patients

Retrieved on: 
Monday, March 15, 2021

Under the agreement, Newron will sponsor the study and be responsible for its development and execution, as well as leading on all related regulatory interactions.

Key Points: 
  • Under the agreement, Newron will sponsor the study and be responsible for its development and execution, as well as leading on all related regulatory interactions.
  • Ravi Anand, CMO of Newron, said: "Previous pre-clinical and clinical studies have provided preliminary evidence of the efficacy of safinamide in reducing dyskinesia.
  • Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
  • Anand R: Safinamide is associated with clinically important improvement in motor symptoms in fluctuating PD patients as add-on to levodopa (SETTLE).

Newron and Zambon Sign Agreement for Potentially Pivotal Study with safinamide in Parkinson’s Disease Patients

Retrieved on: 
Monday, March 15, 2021

Under the agreement, Newron will sponsor the study and be responsible for its development and execution, as well as leading on all related regulatory interactions.

Key Points: 
  • Under the agreement, Newron will sponsor the study and be responsible for its development and execution, as well as leading on all related regulatory interactions.
  • Newron and Zambon will evenly share the cost of the study.
  • The double-blind, placebo-controlled study is intended to be performed in the US, Europe and Asia/Australia, with the aim of a label extension for safinamide in key markets.
  • Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.

Eisai to Launch Parkinson's Disease Treatment Equfina in South Korea

Retrieved on: 
Monday, February 1, 2021

TOKYO, Feb 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has launched the Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide").

Key Points: 
  • TOKYO, Feb 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has launched the Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide").
  • The estimated number of patients with Parkinson's disease is approximately 150,000 in South Korea.
  • This disease is designated as a rare intractable disease in South Korea.
  • Together with providing Equfina as a new treatment option for Parkinson's disease to patients in South Korea, Eisai will make further contributions to address the diversified needs of Parkinson's disease patients and their families in Asia, and increase the benefits provided to them.

Lexicon Pharmaceuticals Receives Fast Track Designation From the FDA for LX9211 for Diabetic Peripheral Neuropathic Pain

Retrieved on: 
Friday, December 11, 2020

THE WOODLANDS, Texas, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of LX9211 in diabetic peripheral neuropathic pain.

Key Points: 
  • THE WOODLANDS, Texas, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of LX9211 in diabetic peripheral neuropathic pain.
  • The FDAs Fast Track designation of LX9211 reflects the serious unmet medical need of people suffering from diabetic peripheral neuropathic pain, said Praveen Tyle, Ph.D., executive vice president of research and development.
  • Lexicon is currently enrolling patients with diabetic peripheral neuropathic pain in a Phase 2 proof-of-concept study of LX9211 and is preparing to initiate a second Phase 2 clinical trial of LX9211 in post-herpetic neuralgia.
  • Programs receiving Fast Track designation may benefit from early and frequent interactions with the FDA over the course of drug development.

China Pregabalin Market Investigation Report, 2015-2020 & 2020-2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 12, 2020

The "Investigation Report on the Chinese Pregabalin Market, 2020-2024 " report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on the Chinese Pregabalin Market, 2020-2024 " report has been added to ResearchAndMarkets.com's offering.
  • For example, the number of epileptics in China has exceeded 10 million and increases by 500 thousand every year.
  • Chongqing Succeway Pharmaceutical Co., Ltd.'s Pregabalin (trade name: Lairuike) was put in the market after obtaining the production license in 2013 and is gradually taking market share from Pfizer.
  • 2 Market Overview of Pregabalin in China, 2013-2018
    2.3 Investigation on Market Size of Pregabalin by Dosage Form in China, 2013-2018
    3 Investigation on Market Share of Major Pregabalin Manufacturers in China, 2013-2018
    3.3 Chongqing Succeway Pharmaceutical Co., Ltd.
    4 Sales Price of Pregabalin in China Market, 2019
    4.2.2 Chongqing Succeway Pharmaceutical Co., Ltd. (Lairuike)
    5 Prospects of Pregabalin Market, 2020-2024
    5.3 Forecast on Market Size of Pregabalin in China, 2020-2024
    View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005627/en/

United States Neuropathic Pain Market and Competitive Landscape Report 2020: Epidemiology, Product Sales & Market Size & Forecasts 2016-2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 11, 2020

The "US Neuropathic Pain Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Neuropathic Pain Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • The latest research US Neuropathic Pain Market and Competitive Landscape Highlights - 2020, provides comprehensive insights into Neuropathic Pain pipeline products, Neuropathic Pain epidemiology, Neuropathic Pain market valuations and forecast, Neuropathic Pain drugs sales and competitive landscape in the US.
  • Neuropathic Pain pipeline: Find out the products in clinical trials for the treatment of Neuropathic Pain by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Neuropathic Pain drugs: Identify key products marketed and prescribed for Neuropathic Pain in the US, including trade name, molecule name, and company
    Neuropathic Pain market valuations: Find out the market size for Neuropathic Pain drugs in 2019 in the US.
  • Find out how the market advanced from 2016 and forecast to 2025
    Neuropathic Pain drugs market share: Find out the market shares for key Neuropathic Pain drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Neuropathic Pain products